AU2002334355A1 - Protein tyrosine kinase inhibitors - Google Patents
Protein tyrosine kinase inhibitorsInfo
- Publication number
- AU2002334355A1 AU2002334355A1 AU2002334355A AU2002334355A AU2002334355A1 AU 2002334355 A1 AU2002334355 A1 AU 2002334355A1 AU 2002334355 A AU2002334355 A AU 2002334355A AU 2002334355 A AU2002334355 A AU 2002334355A AU 2002334355 A1 AU2002334355 A1 AU 2002334355A1
- Authority
- AU
- Australia
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- protein tyrosine
- protein
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31718601P | 2001-09-06 | 2001-09-06 | |
US60/317,186 | 2001-09-06 | ||
IL145329 | 2001-09-09 | ||
IL14532901A IL145329A0 (en) | 2001-09-09 | 2001-09-09 | Protein tyrosine kinase inhibitors |
PCT/IL2002/000740 WO2003020698A2 (en) | 2001-09-06 | 2002-09-05 | Protein tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002334355A1 true AU2002334355A1 (en) | 2003-03-18 |
Family
ID=26324042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002334355A Abandoned AU2002334355A1 (en) | 2001-09-06 | 2002-09-05 | Protein tyrosine kinase inhibitors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002334355A1 (en) |
WO (1) | WO2003020698A2 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1988397B8 (en) | 2002-12-19 | 2012-02-15 | The Scripps Research Institute | Compositions and uses for stabilising transthyretin and inhibiting transthyretin misfolding |
KR101102229B1 (en) * | 2003-05-27 | 2012-01-05 | 닐스 리차드 웰쉬 | Use of Tyrosine Kinase Inhibitor to Treat Diabetes |
US7442709B2 (en) | 2003-08-21 | 2008-10-28 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine c-Kit inhibitors |
CA2536174A1 (en) * | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine-derivatives as c-kit inhibitors |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
WO2005062795A2 (en) * | 2003-12-19 | 2005-07-14 | Plexxikon, Inc. | Compounds and methods for development of ret modulators |
WO2005112913A1 (en) | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
US7960548B2 (en) * | 2005-04-29 | 2011-06-14 | The Ohio State University Research Foundation | Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis |
US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
JP5301999B2 (en) | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | CETP inhibitor |
WO2007059230A2 (en) | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
ES2385849T3 (en) | 2006-05-02 | 2012-08-01 | Abbott Laboratories | The substituted 1H-benzimidazol-4-carboxamides are potent inhibitors of PARP |
EP1860104A1 (en) * | 2006-05-22 | 2007-11-28 | Aptanomics | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
AU2007329480A1 (en) * | 2006-12-05 | 2008-06-12 | National Chio Tung University | Indazole compounds |
WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
PL2265607T3 (en) | 2008-02-15 | 2017-07-31 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
BRPI0910921B1 (en) | 2008-04-16 | 2022-06-21 | Portola Pharmaceuticals, Inc | Syk kinase protein inhibitors, pharmaceutical composition, kit and uses of said inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
CA2723185A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2010083199A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
CN110269838A (en) | 2009-04-03 | 2019-09-24 | 豪夫迈罗氏公司 | Propane -1- sulfonic acid { 3- [5- (the chloro- phenyl of 4-) -1H- pyrrolo- [2,3-b] pyridine -3- carbonyl] -2,4- difluorophenyl }-amide compositions and application thereof |
MX2012005284A (en) | 2009-11-06 | 2012-06-28 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
MY191934A (en) | 2010-05-20 | 2022-07-19 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
US20140037642A1 (en) | 2011-02-02 | 2014-02-06 | Amgen Inc. | Methods and compositions relating to inhibition of igf-1r |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (en) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | Solid forms of a pharmaceutically active substance |
MX2014003043A (en) | 2011-09-16 | 2015-02-05 | Pfizer | Solid forms of a transthyretin dissociation inhibitor. |
US8877760B2 (en) | 2011-11-23 | 2014-11-04 | Portola Pharmaceuticals, Inc. | Substituted pyrazine-2-carboxamide kinase inhibitors |
CN105646517A (en) * | 2012-03-22 | 2016-06-08 | 巴塞利亚药业(中国)有限公司 | Preparation methods of natural product Hirtellanine B and derivatives thereof and application of natural product Hirtellanine B and derivatives thereof in preparation of drug for treating tumor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | Substituted pyrimidinyl kinase inhibitors |
GB201223265D0 (en) | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
DK3322706T3 (en) | 2015-07-16 | 2021-02-01 | Array Biopharma Inc | SUBSTITUTED PYRAZOLO [1,5-A] PYRIDINE COMPOUNDS AS RIGHT CHINESE INHIBITORS |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
JP7060694B2 (en) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrolo [2,3-D] pyrimidine compounds as RET kinase inhibitors |
JP7061195B2 (en) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [3,4-d] pyrimidine compound as a RET kinase inhibitor |
ES2922314T3 (en) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Fused Heterocyclic Compounds as RET Kinase Inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9610051A (en) * | 1995-08-02 | 1999-12-21 | Univ Newcastle Ventures Ltd | Use of a compound, preparation process, pharmaceutical formulation or composition containing a compound, pharmaceutical composition, and therapeutic treatment process |
ID28787A (en) * | 1998-11-03 | 2001-07-05 | Basf Ag | SUBSTITUTED 2-PHENILBENZIMIDAZOL, ITS MAKING AND USE OF IT |
-
2002
- 2002-09-05 AU AU2002334355A patent/AU2002334355A1/en not_active Abandoned
- 2002-09-05 WO PCT/IL2002/000740 patent/WO2003020698A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003020698A3 (en) | 2004-03-18 |
WO2003020698A2 (en) | 2003-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002334355A1 (en) | Protein tyrosine kinase inhibitors | |
AU2437900A (en) | Piperidinylquinolines as protein tyrosine kinase inhibitors | |
AU2002361577A1 (en) | Tyrosine kinase inhibitors | |
AU2003299651A1 (en) | Tyrosine kinase inhibitors | |
EP1381598A4 (en) | Novel tyrosine kinase inhibitors | |
HUP0400300A3 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
AU2003298942A1 (en) | Tyrosine kinase inhibitors | |
AU2003282891A1 (en) | Novel tyrosine kinases inhibitors | |
AU2000240570A1 (en) | Pyrrolopyrimidines as tyrosine kinase inhibitors | |
HK1068134A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
AU2002305260A1 (en) | Pyrazole derived kinase inhibitors | |
AU2002357193A1 (en) | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | |
AU2002348394A1 (en) | Tyrosine kinase inhibitors | |
AU2003275282A1 (en) | Novel tyrosine kinase inhibitors | |
AU2002953255A0 (en) | Protein kinase inhibitors | |
AU2002348020A1 (en) | Tyrosine kinase inhibitors | |
AU2001247882A1 (en) | Tricyclic protein kinase inhibitors | |
AU2002348393A1 (en) | Tyrosine kinase inhibitors | |
AU2576501A (en) | Protein kinase inhibitors | |
AU2002323406A1 (en) | Tyrosine kinase inhibitors | |
AU2002327534A1 (en) | Tyrosine kinase inhibitors | |
AUPS251502A0 (en) | Protein kinase inhibitors | |
AU2002253350A1 (en) | 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors | |
AU2002304001A1 (en) | Tyrosine kinase inhibitors | |
AU2002326865A1 (en) | Tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |